Literature DB >> 18772244

Epithelial ovarian cancer: testing the 'androgens hypothesis'.

Catherine M Olsen1, Adèle C Green, Christina M Nagle, Susan J Jordan, David C Whiteman, Christopher J Bain, Penelope M Webb.   

Abstract

In 1998, Risch proposed a hypothesis for the pathogenesis of ovarian cancer relating to the role of androgens in stimulating epithelial cell proliferation. Although this hypothesis has been widely discussed, direct evidence to support it is scant. To address this issue, we have conducted a detailed analysis of factors possibly associated with high circulating levels of androgens, including polycystic ovary syndrome (PCOS), hirsutism and acne (all clinically associated with hyperandrogenism) using the data collected in an Australia-wide, population-based case-control study. Cases aged 18-79 years with a new diagnosis of invasive epithelial ovarian cancer (n=1276) or borderline malignant tumour (n=315) were identified through a network of clinics and cancer registries throughout Australia. Controls (n=1508) were selected from the National Electoral Roll. Women self-reported a history of PCOS, acne, hirsutism and also use of testosterone supplements or the androgenic medication Danazol. We found no evidence that a history of PCOS, acne or hirsutism was associated with ovarian cancer overall, or with specific subtypes, with the exception of serous borderline tumours that were positively associated with a history of PCOS (OR 2.6; 95% CI 1.0-6.1). Women who had ever used testosterone supplements had an increased risk of ovarian cancer (OR 3.7; 95% CI 1.1-12.0); however, use of the androgenic medication Danazol did not increase risk (OR 1.0; 95% CI 0.4-2.9). Overall, our results do not support the hypothesis that androgen-related disorders increase the risk of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18772244     DOI: 10.1677/ERC-08-0075

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  24 in total

Review 1.  Revisiting the role of antiandrogen strategies in ovarian cancer.

Authors:  Dionysis Papadatos-Pastos; Konstantin J Dedes; Johann S de Bono; Stanley B Kaye
Journal:  Oncologist       Date:  2011-09-23

2.  Flutamide and biomarkers in women at high risk for ovarian cancer: preclinical and clinical evidence.

Authors:  Christine Gruessner; Angelika Gruessner; Katherine Glaser; Nisreen AbuShahin; Yi Zhou; Cynthia Laughren; Heather Wright; Samantha Pinkerton; Xiaofang Yi; Jha'nae Stoffer; Masoud Azodi; Wenxin Zheng; Setsuko K Chambers
Journal:  Cancer Prev Res (Phila)       Date:  2014-06-20

3.  Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium.

Authors:  Holly R Harris; Ana Babic; Penelope M Webb; Christina M Nagle; Susan J Jordan; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Marc T Goodman; Francesmary Modugno; Roberta B Ness; Kirsten B Moysich; Susanne K Kjær; Estrid Høgdall; Allan Jensen; Joellen M Schildkraut; Andrew Berchuck; Daniel W Cramer; Elisa V Bandera; Nicolas Wentzensen; Joanne Kotsopoulos; Steven A Narod; Catherine M Phelan; John R McLaughlin; Hoda Anton-Culver; Argyrios Ziogas; Celeste L Pearce; Anna H Wu; Kathryn L Terry
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-11-15       Impact factor: 4.254

Review 4.  Diagnosis, treatment, and follow-up of borderline ovarian tumors.

Authors:  Daniela Fischerova; Michal Zikan; Pavel Dundr; David Cibula
Journal:  Oncologist       Date:  2012-09-28

5.  Early pregnancy sex steroids and maternal risk of epithelial ovarian cancer.

Authors:  Helena Schock; Heljä-Marja Surcel; Anne Zeleniuch-Jacquotte; Kjell Grankvist; Hans-Åke Lakso; Renée Turzanski Fortner; Rudolf Kaaks; Eero Pukkala; Matti Lehtinen; Paolo Toniolo; Eva Lundin
Journal:  Endocr Relat Cancer       Date:  2014       Impact factor: 5.678

6.  Long and irregular menstrual cycles, polycystic ovary syndrome, and ovarian cancer risk in a population-based case-control study.

Authors:  H R Harris; L J Titus; D W Cramer; K L Terry
Journal:  Int J Cancer       Date:  2016-10-06       Impact factor: 7.396

7.  Cancer risk among infertile women with androgen excess or menstrual disorders (including polycystic ovary syndrome).

Authors:  Louise A Brinton; Kamran S Moghissi; Carolyn L Westhoff; Emmet J Lamb; Bert Scoccia
Journal:  Fertil Steril       Date:  2009-11-25       Impact factor: 7.329

Review 8.  Hormone response in ovarian cancer: time to reconsider as a clinical target?

Authors:  Francesmary Modugno; Robin Laskey; Ashlee L Smith; Courtney L Andersen; Paul Haluska; Steffi Oesterreich
Journal:  Endocr Relat Cancer       Date:  2012-11-09       Impact factor: 5.678

9.  Radiolabeled 5-iodo-3'-O-(17beta-succinyl-5alpha-androstan-3-one)-2'-deoxyuridine and its 5'-monophosphate for imaging and therapy of androgen receptor-positive cancers: synthesis and biological evaluation.

Authors:  Zbigniew P Kortylewicz; Jessica Nearman; Janina Baranowska-Kortylewicz
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

10.  Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study.

Authors:  Suzanne C Dixon; Christina M Nagle; Aaron P Thrift; Paul Dp Pharoah; Celeste Leigh Pearce; Wei Zheng; Jodie N Painter; Georgia Chenevix-Trench; Peter A Fasching; Matthias W Beckmann; Diether Lambrechts; Ignace Vergote; Sandrina Lambrechts; Els Van Nieuwenhuysen; Mary Anne Rossing; Jennifer A Doherty; Kristine G Wicklund; Jenny Chang-Claude; Anja Rudolph; Kirsten B Moysich; Kunle Odunsi; Marc T Goodman; Lynne R Wilkens; Pamela J Thompson; Yurii B Shvetsov; Thilo Dörk; Tjoung-Won Park-Simon; Peter Hillemanns; Natalia Bogdanova; Ralf Butzow; Heli Nevanlinna; Liisa M Pelttari; Arto Leminen; Francesmary Modugno; Roberta B Ness; Robert P Edwards; Joseph L Kelley; Florian Heitz; Beth Y Karlan; Susanne K Kjær; Estrid Høgdall; Allan Jensen; Ellen L Goode; Brooke L Fridley; Julie M Cunningham; Stacey J Winham; Graham G Giles; Fiona Bruinsma; Roger L Milne; Melissa C Southey; Michelle A T Hildebrandt; Xifeng Wu; Karen H Lu; Dong Liang; Douglas A Levine; Maria Bisogna; Joellen M Schildkraut; Andrew Berchuck; Daniel W Cramer; Kathryn L Terry; Elisa V Bandera; Sara H Olson; Helga B Salvesen; Liv Cecilie Thomsen; Reidun K Kopperud; Line Bjorge; Lambertus A Kiemeney; Leon F A G Massuger; Tanja Pejovic; Linda S Cook; Nhu D Le; Kenneth D Swenerton; Angela Brooks-Wilson; Linda E Kelemen; Jan Lubiński; Tomasz Huzarski; Jacek Gronwald; Janusz Menkiszak; Nicolas Wentzensen; Louise Brinton; Hannah Yang; Jolanta Lissowska; Claus K Høgdall; Lene Lundvall; Honglin Song; Jonathan P Tyrer; Ian Campbell; Diana Eccles; James Paul; Rosalind Glasspool; Nadeem Siddiqui; Alice S Whittemore; Weiva Sieh; Valerie McGuire; Joseph H Rothstein; Steven A Narod; Catherine Phelan; Harvey A Risch; John R McLaughlin; Hoda Anton-Culver; Argyrios Ziogas; Usha Menon; Simon A Gayther; Susan J Ramus; Aleksandra Gentry-Maharaj; Anna H Wu; Malcolm C Pike; Chiu-Chen Tseng; Jolanta Kupryjanczyk; Agnieszka Dansonka-Mieszkowska; Agnieszka Budzilowska; Beata Spiewankiewicz; Penelope M Webb
Journal:  Int J Epidemiol       Date:  2016-07-10       Impact factor: 7.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.